Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C.

Journal of postgraduate medicine - 1 Jan 2000

Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Aizawa Y

Abstract excerpt

BACKGROUND AND RATIONALE: Most patients with chronic hepatitis C show virological response to telaprevir-based triple therapy, and achieve an end-of-treatment response (ETR). However, some patients showing ETR develop virological relapse. This study was carried out to evaluate factors associated with relapse after triple therapy. MATERIALS AND METHODS: A prospective, multicentric study was conducted in chronic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon-alpha
Share to Interferon alpha-2
Share to Interferons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukins

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Recurrence

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 26732192
DOI: 10.4103/0022-3859.173191
PMCID: PMC4944324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C.PMID 26732192Read ↗

Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.Semantic proximity Read ↗

Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.Semantic proximity Read ↗

Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients.Semantic proximity Read ↗

Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response.Semantic proximity Read ↗

Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.Semantic proximity Read ↗

Identifying HCV genotype 1 patients at risk of relapse.Semantic proximity Read ↗

Telaprevir for retreatment of HCV infection.Semantic proximity Read ↗

Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.Semantic proximity Read ↗

Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.Semantic proximity Read ↗

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.Semantic proximity Read ↗

α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.